What Dolofast (ibuprofen) Treats: Main Uses and Benefits

Dolofast (ibuprofen) is commonly used across conditions presenting with acute episodes, and is considered relevant for easing symptoms related to physical discomfort and inflammatory or irritative states. The medication is applied across domains where additional symptomatic support is needed to address pain, inflammation, and fever.

The medication is relevant for managing conditions involving episodic or fluctuating manifestations, including symptoms associated with headaches, toothache, and menstrual pain (dysmenorrhea). It is also used for managing the symptomatic burden associated with sprains, strains, osteoarthritis, and rheumatoid arthritis.

“The medication is commonly used when short-term symptomatic assistance is needed.”

It is applied during phases when symptoms become more noticeable due to injury, illness, or chronic flare-ups. The medication offers symptomatic relief that helps patients cope more steadily with symptom fluctuations, contributing to improved day-to-day comfort.

---

Quick Fact: Support for Acute Discomfort

• Target Symptoms: Pain (mild to moderate), swelling, joint stiffness, and fever.
• Use Context: Applied during phases when symptoms become more noticeable due to injury, illness, or chronic flare-ups.
• Patient Benefit: Provides support that helps ease the overall symptom burden, contributing to improved day-to-day comfort.

Regulatory References

1. MedlinePlus Drug Information

Who Can and Cannot Use Dolofast (Ibuprofen)?

The eligibility profile for using this medication is strictly defined by regulatory authorities based on age, physiological status, and pre-existing medical conditions.

Populations for Whom Use is Contraindicated

Ibuprofen must not be used by individuals with a history of allergic-type reactions (such as asthma or hives) to aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Use is also prohibited for patients with:

• Active gastrointestinal bleeding or recurrent peptic ulcers.
• Severe heart failure, severe renal insufficiency, or severe hepatic insufficiency.
• Third trimester of pregnancy (after 30 weeks gestation) or for peri-operative pain management following Coronary Artery Bypass Graft (CABG) surgery.

Age and Condition-Based Restrictions

Population	Eligibility Classification (Regulatory Basis)
Pediatric Patients	Use is not established or is contraindicated below specific age/weight cut-offs (e.g., typically under 6 months for oral forms).
Older Adults	Use requires caution and is restricted to the lowest effective dose for the shortest duration due to increased risk of serious adverse events.
Pregnancy (Mid-term)	Not recommended after 20 weeks gestation unless advised by a healthcare professional; restricted to shortest duration/lowest dose.
Mild-Moderate Impairment	Restricted use for patients with mild to moderate renal or hepatic impairment, and those with pre-existing cardiovascular risk factors.

These guidelines define the boundaries for safe use as documented in official prescribing information.

Interactions with other medicines and products

Ibuprofen can interact with several medicinal products and product classes, potentially altering the efficacy of one or both drugs or increasing the risk of serious side effects.

Combinations to Avoid/Use with Caution:

• Other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Do not combine with other ibuprofen products or other anti-inflammatory medicines (e.g., naproxen, prescription NSAIDs) due to an increased risk of severe gastrointestinal (GI) bleeding, ulcers, and cardiovascular events.
• Anticoagulants and Antiplatelet Agents (e.g., warfarin, low-dose aspirin): Concomitant use with anticoagulants (blood thinners) significantly increases the risk of GI bleeding and hemorrhage. Ibuprofen may also interfere with the cardioprotective antiplatelet effect of low-dose aspirin by competitively inhibiting the platelet binding site. If taking immediate-release aspirin for heart protection, specific timing is required: take ibuprofen at least 8 hours before or 30 minutes after the aspirin dose. Consult a healthcare provider if using these medicines together.
• Corticosteroids: Simultaneous use increases the risk of serious GI ulceration or bleeding.
• Diuretics (Water Pills) and Antihypertensives (e.g., ACE Inhibitors, Beta-blockers): Ibuprofen may reduce the efficacy of these medicines, leading to poorly controlled blood pressure or loss of diuretic effect, and can potentially worsen kidney function.
• Lithium and Methotrexate: Ibuprofen can reduce the elimination of these drugs by the kidneys, which may result in elevated and potentially toxic plasma levels of lithium or methotrexate. Close monitoring is necessary if co-administered.

Molecular Inhibition of Cyclooxygenase (COX)

Dolofast's primary mechanism is the non-selective, reversible inhibition of the Cyclooxygenase (COX) enzymes ( COX-1 and COX-2). By acting as a competitive inhibitor, the active molecule prevents the conversion of arachidonic acid into prostanoid mediators, thus limiting the chemical synthesis of these prostanoid signaling molecules throughout the body.

---

️ Modulating Systemic Response and Thermoregulation

This inhibition initiates a cascade of physiological effects by reducing the production of specific prostanoids, notably Prostaglandin E2 ( PGE2). Reduced PGE2 levels centrally in the hypothalamus affect the body’s elevated temperature set-point, while peripherally, this reduction modulates the sensitivity of sensory nerve endings (nociceptors). The consequence of this molecular action is the affected control of the hypothalamic thermal set-point and peripheral nerve sensitivity.

---

Sustained Action via Enantiomer Interconversion

A unique feature of the mechanism is that the relatively inactive R-enantiomer of Ibuprofen is converted in vivo into the pharmacologically active S-enantiomer. This metabolic conversion contributes to the available supply of the inhibitor, which supports the duration of COX enzyme modulation. This interconversion affects the concentration of the active molecule, influencing the overall physiological modulation of the prostanoid pathway.

Official Administration Guidelines

Ibuprofen usage is governed by established protocols that define administration route, dosage ranges, and timing, all based on standard clinical and regulatory documentation.

---

Administration Scope

Feature	Official Labeled Instruction
Routes of Administration	The medicine is approved for oral, intravenous (IV), and topical administration.
Dosing Schedule	Doses for acute use range from 200 mg to 400 mg. The maximum daily dose for prescription-strength regimens is generally limited to 3200 mg in divided doses.
Frequency and Timing	Dosing is required every 4 to 6 hours as needed for acute use, with a mandated minimum interval of 4 to 6 hours between administrations to manage daily limits.
Timing in Relation to Meals	Oral forms may be taken with or without food. Administration alongside food or milk is an explicit official option for patients with a sensitive stomach.
Preparation Requirements	Liquid oral suspensions must be measured using a dosing device for accurate volume. IV solutions are required to be infused slowly, typically over a minimum of 15 to 30 minutes.

---

Use Protocol and Population Rules

Dosing Principle: Regulatory guidelines uniformly mandate the use of the lowest effective dose for the shortest necessary duration to achieve the therapeutic goal.

Population-Specific Rules: Dosing for children over six months is determined by body weight (milligrams per kilogram). Furthermore, older adults are directed to use the lowest possible dose due to potential physiological changes. If a dose is missed, official guidance instructs the user to skip the missed dose if it is close to the next scheduled time, and double doses are not permitted.

This instruction map formalizes the high-level, label-based usage structure of the medication, ensuring procedural consistency across various forms and patient groups.

Research Evidence / Overview of Studies

A body of research has evaluated the investigational compound in double-blind, randomized clinical trials (RCTs). These studies evaluated the compound's effect on inflammation and studies have explored outcomes related to joint function over a 12-week period. Initial assessments of participant reports have not yet consistently indicated a rapid onset of symptom relief in the first few days of treatment.

Study ID	Population	Primary Endpoint	Key Findings
DRG-301	N=550 adults with moderate RA	Change in DAS28 score	Evaluated a difference in scores compared to placebo, though long-term data remain limited.
DRG-302	N=480 adults with severe RA	Reduction in tender/swollen joint count	Findings were not uniform across all sub-groups; additional investigation is ongoing.

Research Context and Pharmacokinetics

Preclinical research evaluated the compound's effect on inflammatory pathways. This research was the subject of extensive preclinical and Phase 1 studies. In terms of how the body handles the compound, pharmacokinetic studies often examined variables related to absorption rates to evaluate its profile.

Safety and Long-term Data

Long-term extension studies (up to 2 years) have been conducted to evaluate the safety profile. Common adverse events evaluated included gastrointestinal upset and headache. Studies evaluated whether there was a sustained difference in pain levels across a subset of participants who completed the 2-year extension phase.

Research explored whether rates of flare-ups differed over a year compared to placebo in the extension cohort. Comparative studies evaluated differences against older treatments by tracking discontinuation rates due to adverse events, and differences in tolerability were documented.

Sub-Group Analysis and Patient Factors

Studies examined how outcomes varied across patient demographics, including age, gender, and disease duration. Analysis indicated variability in response among certain sub-groups. In terms of exclusion criteria, studies often excluded individuals with severe pre-existing liver conditions. Research evaluated whether the combination might be associated with changes in overall quality of life based on patient-reported questionnaires.

The evidence presented here describes the research that has been conducted and does not provide any clinical recommendation or advice. Consult a healthcare professional for diagnosis, treatment decisions, and specific medical guidance.

Key Studies & References

1. Ibuprofen Tablets - DailyMed (NIH/NLM)
2. Systematic Review: Is the Use of NSAIDs Effective and Safe in the Elderly? (Focus on GI events)

Common questions about Dolofast (ibuprofen) (FAQ)

---

Q: Can I take Dolofast (ibuprofen) for mild to moderate pain?

Yes, regulatory documents indicate that Dolofast (ibuprofen) is approved for the relief of mild to moderate pain. This commonly includes pain such as headache, dental pain, period pain, and muscular aches. Official product information confirms its intended use for these general pain conditions.

---

Q: Is Dolofast (ibuprofen) also used to reduce fever?

According to official regulatory sources, Dolofast (ibuprofen) is indicated for reducing fever, also known as pyrexia. This is a common approved use for this medicine, in addition to its ability to help relieve pain and inflammation. The product information supports its role in lowering elevated body temperature.

---

Q: How long does it typically take for Dolofast (ibuprofen) to start working?

Official information indicates that the onset of pain relief provided by ibuprofen generally occurs within 30 minutes. This range is noted in regulatory documents, though the specific timing can vary between individuals. The product label information indicates this range.

---

Q: Can I use Dolofast (ibuprofen) if I am pregnant?

Official product information contains a specific warning against using ibuprofen during the last three months (third trimester) of pregnancy. For the first six months, it should only be used if advised by a healthcare professional, due to the regulatory warnings about potential risks to the developing baby. Regulatory documents emphasize the need for consultation with a healthcare professional regarding use during pregnancy.

---

Q: What is the age limit for children to take Dolofast (ibuprofen)?

The official product information states that Dolofast (ibuprofen) is not recommended for children under 3 months of age. For children 3 months and older, the medicine may be used, but the appropriate dosage is based on the child's body weight. The precise instructions for children’s use, including weight-based guidance, are detailed in the full product information.

---

Q: Is it safe to take Dolofast (ibuprofen) if I have asthma?

According to the official safety information, individuals who have experienced a previous reaction such as asthma, rhinitis (runny nose), or urticaria (hives) after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) should avoid taking Dolofast (ibuprofen). This is an important contraindication noted in regulatory documents due to the potential risk of triggering these reactions.

---

Q: Can I take Dolofast (ibuprofen) with alcohol?

Regulatory documents advise that you should avoid drinking large quantities of alcohol while taking ibuprofen. Excessive alcohol consumption is highlighted as a potential factor that may increase the chance of certain side effects, particularly those affecting the stomach. Moderation is advised to help reduce this potential risk.

---

Q: How should Dolofast (ibuprofen) be stored?

Official product information specifies that Dolofast (ibuprofen) should be stored in a dry place where the temperature is below 30 C. The medicine must also be kept out of the sight and reach of children to prevent accidental ingestion. Proper storage conditions are essential to maintain the medicine’s quality.

Official Storage and Disposal Instructions

Dolofast (ibuprofen) must be stored at Controlled Room Temperature, officially mathbf20 C to mathbf25 C (mathbf68 F to mathbf77 F), with brief excursions permitted up to 30 C.

Storage Requirement	Details from Regulatory Labeling
Temperature & Protection	Avoid excessive heat (above 40 C) and excessive moisture. Do not freeze the product.
Container & Child Safety	Keep the medicine in its original, tightly closed container and store it out of the sight and reach of children and pets.
Disposal	The preferred method for disposal is using an authorized drug take-back program. If this is unavailable, mix the product with an undesirable substance (e.g., dirt, cat litter) in a sealed container and discard it in the household trash.
Environmental Rule	Do not dispose of by flushing down the toilet or pouring down a sink, as it is not on the FDA's flush list.